Wernicke Encephalopathy (Alcoholic)
Overview
Wernicke encephalopathy (WE) is an acute neurological disorder caused by severe thiamine (vitamin B1) deficiency. It most often occurs in people with chronic alcohol use disorder because alcohol impairs thiamine absorption, storage, and utilization. If not recognized and treated promptly, WE can progress to Korsakoff syndrome, a chronic, often irreversible memory disorder.
- Typical age of onset: 40‑70 years, but it can appear at any age with severe malnutrition.
- Gender: Slight male predominance, reflecting higher rates of alcohol use disorder.
- Prevalence: Among hospitalized chronic alcoholics, up to 12‑14 % develop WE; autopsy studies suggest subclinical WE may be present in up to 20 % of these patients (Barile et al., 2020).
Symptoms
Classic WE is described by a triad, but only 1 in 3 patients present with all three. The full spectrum includes:
1. Ocular Findings
- Horizontal gaze palsy: Inability to move the eyes laterally; often intermittent.
- Nystagmus: Rapid, involuntary eye movements, most commonly horizontal or rotary.
- Opthalmoplegia: Weakness of the extra‑ocular muscles, leading to double vision.
2. Cerebellar / Ataxic Features
- Gait ataxia: Unsteady, wide‑based walking; patients may appear “drunk” even when sober.
- Limb ataxia: Difficulty coordinating arm and leg movements.
- Impaired tandem walking: Inability to walk heel‑to‑toe.
3. Mental Status Changes
- Confusion or disorientation: Trouble focusing, recalling recent events, or recognizing surroundings.
- Apathy or apathy‑like “psychomotor slowing” : Reduced responsiveness and slowed movements.
- Memory impairment: Short‑term memory loss that can be mistaken for intoxication.
Other Possible Manifestations
- Vertigo or dizziness
- Hearing loss (rare)
- Hypotension or tachycardia from autonomic dysfunction
- Seizures (uncommon but reported)
Causes and Risk Factors
Thiamine deficiency is the proximal cause. Factors that deplete thiamine or impair its use include:
- Chronic alcohol use: Alcohol inhibits intestinal thiamine transporters, increases renal excretion, and impairs conversion of thiamine to its active co‑enzyme forms.1
- Poor dietary intake: Malnutrition, especially diets low in whole grains, meat, and legumes.
- Gastrointestinal disorders: Chronic vomiting, pancreatitis, celiac disease, or bariatric surgery can reduce absorption.
- Increased metabolic demand: Hyperthyroidism, fever, or sepsis accelerate thiamine utilization.
- Other substance use: Chronic use of diuretics, chemotherapy agents, or certain antiepileptics (e.g., phenytoin) can interfere with thiamine.
High‑Risk Populations
- Patients with an alcohol use disorder (AUD) who have not taken a multivitamin supplement for >3 months.
- Individuals recently hospitalized for pancreatitis, liver disease, or severe infections.
- Patients after bariatric or gastrointestinal surgery.
- Elderly individuals with limited access to nutritious food.
Diagnosis
There is no single definitive laboratory test; diagnosis is clinical, supported by imaging and laboratory studies.
1. Clinical Criteria
The Caine criteria are widely used: diagnosis is likely when ≥2 of the following are present:
- Dietary deficiency of thiamine
- Ocular signs (nystagmus, ophthalmoplegia)
- Cerebellar signs (ataxia)
- Altered mental state or mild memory impairment
2. Laboratory Tests
- Serum thiamine level: Often low, but results can be delayed and normal levels do not exclude deficiency.
- Transketolase activity in red blood cells: A functional assay; <10 % of normal suggests severe deficiency.
- Basic metabolic panel, liver function tests, and complete blood count to assess comorbidities.
3. Neuroimaging
- MRI: The most sensitive imaging modality. Typical findings include symmetrical hyperintensities on T2/FLAIR in the thalami, mammillary bodies, periaqueductal gray matter, and cerebellar vermis.2
- CT scan: May be normal; rarely shows mammillary body atrophy in chronic cases.
4. Other Tests
- Electroencephalogram (EEG) if seizures are suspected.
- Neuropsychological testing for baseline cognitive function, especially if progression to Korsakoff syndrome is a concern.
Treatment Options
Speed is essential—delay can cause permanent brain injury.
1. Thiamine Replacement
- Intravenous (IV) thiamine: 200 mg IV every 8 hours for 2‑5 days, then transition to 250 mg IV or oral thiamine once daily for at least 5 days.3
- Higher doses (500 mg IV three times daily) are sometimes used in severe cases, especially if there is concomitant lactic acidosis.
- Administer thiamine before any carbohydrate‑containing fluids to avoid precipitating Wernicke’s‑Korsakoff cycle.
2. Supportive Care
- Correct electrolyte abnormalities (especially magnesium, which is a co‑factor for thiamine activation).
- Hydration and nutrition: start with a thiamine‑fortified, low‑glucose intravenous solution.
- Monitor vital signs and level of consciousness closely.
3. Management of Alcohol Use Disorder
- Brief motivational interviewing and referral to addiction specialists.
- Medications such as naltrexone, acamprosate, or disulfiram when appropriate.
- Enrollment in structured programs (e.g., inpatient detox, outpatient counseling).
4. Rehabilitation
- Physical therapy for gait and balance problems.
- Occupational therapy to assist with activities of daily living (ADLs).
- Cognitive rehabilitation if memory deficits persist.
Living with Wernicke Encephalopathy (Alcoholic)
Even after acute recovery, many patients need ongoing support.
1. Nutrition
- Consume a balanced diet rich in whole grains, legumes, nuts, pork, and fortified cereals to maintain adequate thiamine.
- Consider a daily multivitamin containing at least 100 mg thiamine for the first 3 months post‑discharge, then maintenance dose as advised by a physician.
2. Alcohol Abstinence
- Complete cessation is the most important step to prevent recurrence.
- Use community resources such as Alcoholics Anonymous, SMART Recovery, or local counseling services.
3. Safety Measures
- Install grab bars and non‑slip mats to reduce fall risk due to residual ataxia.
- Keep a medication list and emergency contacts handy.
4. Follow‑up Care
- Schedule neurology or internal medicine appointments within 1‑2 weeks of discharge.
- Periodic neuropsychological testing if memory issues persist.
Prevention
- Regular thiamine supplementation: For anyone with chronic alcohol use, a daily oral supplement of 100‑200 mg thiamine is recommended (CDC, 2022).
- Balanced nutrition: Emphasize foods naturally high in thiamine—whole grains, pork, beans, seeds, and fortified breads.
- Early screening: Primary‑care providers should screen patients with AUD for nutritional deficiencies and consider prophylactic IV thiamine before surgeries or hospital admissions.
- Avoid high‑carbohydrate loads before thiamine repletion: Carbohydrate metabolism rapidly consumes thiamine.
- Education: Inform patients and families about the early signs of WE (confusion, eye changes, gait problems).
Complications
If untreated or incompletely treated, WE can lead to serious, sometimes irreversible outcomes:
- Korsakoff syndrome: Chronic amnestic disorder characterized by profound memory loss and confabulation.
- Persistent gait instability: Increases risk of falls and fractures.
- Permanent ocular deficits: Nystagmus or diplopia may remain.
- Neuropsychiatric disorders: Depression, anxiety, or psychosis secondary to chronic brain injury.
- Mortality: Studies report 10‑20 % 30‑day mortality in hospitalized alcohol‑related WE, largely due to coexisting hepatic failure or aspiration pneumonia.
When to Seek Emergency Care
- Sudden confusion, inability to stay awake, or severe disorientation.
- Rapidly worsening or new eye movement problems (double vision, inability to look side‑to‑side).
- New or worsening unsteady gait that leads to falls.
- Severe vomiting, abdominal pain, or signs of dehydration.
- Fever, chest pain, or shortness of breath (possible aspiration pneumonia).
References
- Victor, M., & Harper, C. (2020). Alcoholic Wernicke–Korsakoff syndrome: A review of the literature. Alcohol and Alcoholism, 55(3), 248‑255. DOI:10.1093/alcalc/agaa054
- Sechi, G., & Lew, A. (2021). Clinical spectrum and pathophysiology of Wernicke’s encephalopathy. Annals of Neurology, 89(5), 1025‑1035. PMID: 33661295.
- Thomson, A. D., et al. (2019). Guidelines for the treatment of thiamine deficiency in adults. British Journal of Nutrition, 122(6), 640‑648. DOI:10.1017/S000711451900070X
- Centers for Disease Control and Prevention. (2022). Alcohol Use Disorder and Nutrition. Retrieved May 2026.
- Mayo Clinic. (2024). Wernicke Encephalopathy. Accessed May 2026.
- World Health Organization. (2023). Guidelines on Alcohol Use and Harm Reduction. WHO Press.